Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Along with aging population, cancer incidence and mortality are increasing. However, despite advances in oncology and surgery, long-term survival of cancer patients is far from optimal. Dexmedetomidine is a highly selective alpha 2 adrenergic receptor agonist with sedative, analgesic, and anxiolytic effects. Studies showed that perioperative use of dexmedetomidine reduces delirium and some non-delirium complications after surgery. In long-term follow-up studies of older patients who, for other reasons, were randomized to receive either dexmedetomidine or placebo during intra- or postoperative period, dexmedetomidine use was associated with improved long-term survival. This multicenter randomized trial aims to investigate the effect of perioperative dexmedetomidine on long-term outcomes in older patients undergoing cancer surgery.
Eligibility Criteria
Inclusion criteria: 1. Aged 60 years or older. 2. Scheduled to undergo radical surgery for cancer under general anesthesia, with an expected surgical duration of 2 hours or longer. 3. Required patient-controlled intravenous analgesia after surgery. Exclusion criteria: 1. Inability to communicate preoperatively due to visual, auditory, verbal. or other reasons. 2. Surgery for breast cancer or intracranial tumor. 3. Preoperative severe sinus bradycardia (\<50 beats per minute), sick sinus syndrome，or second-degree or above atrioventricular block without pacemaker. 4. Severe hepatic dysfunction (Child-Pugh class C). 5. Severe renal dysfunction (requirement of renal replacement therapy before surgery). 6. Enrolled in other clinical studies.